Replay
Replay is genome writing company reprogramming biology by writing and delivering big DNA
Replay has raised €54M across 1 funding round from 7 investors, most recently a Seed round in Jul 2022. Based in London, UK; active in Healthtech. Data as of 28 Oct 2026.
London, UKwww.replay.bio ↗
Total raised
€54M
€54,326,353
Funding rounds
1
Investors
7
distinct backers
Active since
2022-07
latest 2022-07
Funding by year
EUR raised per yearReplay — funding by year — interactive chart.
Data table
| Replay — funding by year | |
|---|---|
| 2022 | €54M |
Signals
High confidenceRaise-next likelihood8
base rate 44% for Seed
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-07-26 | Seed | €54M | Artis Ventures,Axial,DeciBio Ventures,KKR,Lansdowne Partners,OMX Ventures+1 more | View deal → |
Related news
- Replay Raises $55M in Seed Fundingfinsmes.com · 2022-07
Similar companies
same sector or countryGlobal coverage: FundingData